Art. 3 Regulation (EU) 2020/1043

In forcesince 15 Jul 2020cited 1×
1.

Articles 6 to 11 and 13 to 24 of Directive 2001/18/EC as well as Articles 4 to 13 of Directive 2009/41/EC shall not apply to operations related to the supply and use of medicinal products containing or consisting of GMOs that are intended to treat or prevent COVID-19, including packaging and labelling, storage, transport, destruction, disposal, distribution or administration, with the exception of the manufacturing of the medicinal products, in any of the following cases:

(a)

where such medicinal products have been excluded from the provisions of Directive 2001/83/EC by a Member State pursuant to Article 5(1) of that Directive;

(b)

where such medicinal products have been temporarily authorised by a Member State pursuant to Article 5(2) of Directive 2001/83/EC; or

(c)

where such medicinal products are made available by a Member State pursuant to Article 83(1) of Regulation (EC) No 726/2004.

2.

Where feasible, Member States shall implement appropriate measures to minimise foreseeable negative environmental impacts resulting from the intended or unintended release of the medicinal product into the environment.

  • Ordonnance du Tribunal (cinquième chambre) du 27 septembre 2021. Coordination nationale médicale santé - environnement (CNMSE) e.a. contre PDecision

    En l’espèce, l’article 3 du règlement attaqué suspend l’application des articles 6 à 11 et 13 à 24 de la directive 2001/18/CE, ainsi que les articles 4 à 13 de la directive 2009/41/CE, lesquels prévoient notamment des droits …

    27 Sep 2021 · 62020TO0633